Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog and search the HCV drug pipeline click here; for more information on HCV clinical trials click here
Be sure to check out our other blog: Hepatitis & Tattoos
Friday, November 12, 2010
Bristol-Myers Squibb BARACLUDE® (entecavir) Co-pay Benefit Program Updates
The BARACLUDE Co-pay Benefit Program will allow eligible patients to save up to $200 of co-pay costs monthly, for the next four years, through December, 2014. Bristol-Myers Squibb will now cover the first $200 of a patient’s monthly co-pay or co-insurance costs; the patient will be responsible for any amount over $200. This means that 94.5% of eligible CHB patients with commercial insurance can have a co-pay of $0 per month over the next four years. Restrictions apply to certain patients, including those who reside in Massachusetts and those with prescription benefits funded through Medicare, Medicaid and other federal/state programs.
To access this benefit, eligible patients need to obtain a Co-pay Benefit Card to take to the pharmacy each time they fill their prescription for BARACLUDE. Benefit cards are available through their healthcare provider. Eligible patients who are currently utilizing our Co-pay Benefit Program for BARACLUDE do not need to obtain new benefit cards. These patients will begin receiving these new benefits, subject to the new program end date, upon their next use of their Co-pay Benefit Card.
The Co-pay Benefit Card currently is not valid in Massachusetts or for prescriptions purchased under Medicaid, Medicare, or federal or state programs (including state prescription drug programs, or private indemnity or HMO insurance plans, which reimburse patients for the entire cost of the prescription drugs).
This Co-pay Benefit Program is for eligible commercially insured patients only. For patients with chronic hepatitis B who are uninsured or underinsured, Bristol-Myers Squibb offers other programs to support access to medicines. Bristol-Myers Squibb provides our medicines free of charge to those who qualify through our Access Virology Patient Assistance Program and also participates in the pharmaceutical industry’s Together Rx Access® Program.
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.